Traditional Chinese medicine composition for treating Parkinson's disease and application thereof
By developing a traditional Chinese medicine composition containing Chinese medicine ingredients such as Aconite, Angelica, Morinica, etc., it has solved the poor effect and poor effect of the existing treatment methods on the midline symptoms for Parkinson's disease due to Yang deficiency and wind production and dampness and blood stasis. The problem of reaction has achieved the effect of significantly improving symptoms and delaying the progress of the disease.
Patent Information
- Application Number
- CN202411239836.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-05
- Publication Date
- 2024-11-19
AI Technical Summary
Existing Parkinson's disease treatment methods are poor in the midline symptoms such as gait disorder, posture balance and speech disorders, and lack disease modification and neuroprotective effects. Western medicine treatment may lead to adverse reactions, and surgical and exercise therapy has limited effects.
Develop a traditional Chinese medicine composition, including Aconite, Angelica, Morinica, Atractylodes, Gastrodia elata, Centipede, Centipede, Dried Ginger, Centipede, Turtle Arbor, Pueraria root, Cinnamon twig, White Peony and Licorice, to target yang deficiency and wind and dampness Parkinson's disease in the form of stasis and obstruction improves symptoms through mechanisms such as warming yang, promoting blood circulation, removing dampness, suffocating wind, and relaxing muscles.
It significantly improves the exercise and non-motor symptoms of Parkinson's disease patients, reduces the dosage of Western medicines such as levodopa, reduces the side effects of Western medicines, delays the progress of the disease, and has the effect of neuroprotection and enhancing efficacy and attenuating toxicity.
Smart Images

Figure CN118976090A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of Chinese medicine for preventing and treating encephalopathy, and specifically relates to a Chinese medicine composition for treating Parkinson's disease and application thereof. Background Art
[0002] Parkinson's disease (PD) is a common neurodegenerative disease. Common clinical symptoms include motor symptoms such as resting tremor, bradykinesia, rigidity, and postural disorders, as well as non-motor symptoms such as sensory disorders, autonomic dysfunction, and mental disorders. According to statistics, the prevalence of Parkinson's disease in people over 65 years old in my country is 1.7%. It is estimated that by 2030, the number of Parkinson's disease patients in my country will reach 5 million, accounting for almost half of the global number of patients, bringing a heavy burden to families and society.
[0003] At present, PD is mainly treated with dopaminergic drugs such as Madopar, and other treatments include surgery, exercise, and psychological intervention. Although Western medicine can improve clinical symptoms of resting tremor, bradykinesia, and myotonia to varying degrees, it has poor effects on midline symptoms such as gait disorders, postural balance, and speech disorders, lacks disease modification and neuroprotection, cannot delay disease progression, has a honeymoon period, and long-term use may cause adverse reactions such as end-of-dose phenomenon, switch phenomenon, and dyskinesia. Surgical treatment has strict indications and cannot delay disease progression; other therapies such as exercise therapy and psychological intervention have limited effects.
[0004] Relatively speaking, Chinese herbal compound preparations have the advantages of multi-target and multi-link overall regulation in the treatment of PD, with definite efficacy and fewer adverse reactions. In recent years, some scholars have conducted research on the treatment of PD with traditional Chinese medicine, which has confirmed that Chinese herbal compound preparations have good effects in the treatment of PD and can effectively improve patients' motor symptoms such as tremor and rigidity, as well as non-motor symptoms such as insomnia, anxiety, and constipation. However, at present, traditional Chinese medicine treatment of PD often focuses on the treatment of yin deficiency and wind movement, ignoring the important pathological change of "yang deficiency". In long-term clinical practice, many doctors have realized that the important pathogenesis of "yang deficiency" in PD cannot be ignored, and have achieved good clinical efficacy in treating PD patients from the perspective of warming yang. Therefore, it is an urgent need to develop new Chinese herbal compound preparations with definite efficacy, few side effects, and suitable for long-term use to treat PD. Summary of the invention
[0005] In view of the deficiencies in the prior art, the purpose of the present invention is to provide a Chinese medicine composition for treating PD with wind-generating yang deficiency and dampness and stasis and its application. Animal experiments show that the Chinese medicine composition has a good therapeutic effect on PD model mice induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), specifically: 1. Improve motor dysfunction of PD mice, reduce the loss of dopamine neurons in the substantia nigra of the midbrain, promote dopamine (DA) synthesis, and have a neuroprotective effect; 2. Increase the activity of respiratory chain complexes I to IV in the substantia nigra mitochondria and promote adenosine triphosphate (ATP) production; 3. Regulate metabolic disorders of serum phenylalanine, tyrosine and tryptophan biosynthesis pathways and improve mitochondrial energy metabolism. Clinical studies have confirmed that the Chinese medicine composition is safe and effective for treating PD with wind-generating yang deficiency and dampness and stasis, and can significantly improve the patient's motor symptoms and non-motor symptoms, reduce the daily dosage of Western medicine equivalent to levodopa, reduce the toxic and side effects of Western medicine, reduce the degree of dependence on Western medicine, delay the progression of the disease, and has the effect of increasing efficacy and reducing toxicity, which is worthy of clinical promotion and application.
[0006] The technical solution of the present invention is as follows:
[0007] In a first aspect, the present invention provides a traditional Chinese medicine composition for treating PD, comprising the following traditional Chinese medicine ingredients in a weight distribution ratio: 6-15 parts of aconite root (processed aconite), 6-15 parts of angelica, 5-15 parts of Morinda officinalis, 6-30 parts of Atractylodes macrocephala, 5-15 parts of Gastrodia elata, 3-5 parts of Scolopendra subspinipes, 5-10 parts of dried ginger, 10-25 parts of Acanthopanax senticosus, 15-24 parts of turtle shell, 10-15 parts of Pueraria root, 5-15 parts of cinnamon twig, 10-30 parts of white peony root, and 5-10 parts of liquorice (roasted liquorice).
[0008] Preferably, the composition of the traditional Chinese medicine composition in terms of weight distribution ratio includes: 9 parts of aconite root (processed aconite), 9 parts of angelica, 15 parts of Morinda officinalis, 15 parts of Atractylodes macrocephala, 15 parts of Gastrodia elata, 5 parts of Scolopendra subspinipes, 9 parts of dried ginger, 15 parts of Acanthopanax senticosus, 15 parts of Carapace of Turtle, 15 parts of Pueraria root, 15 parts of cinnamon twig, 15 parts of white peony root, and 9 parts of licorice (roasted licorice).
[0009] In a second aspect, the present invention provides a medicament for treating PD, wherein the pharmaceutical preparation comprises the above-mentioned traditional Chinese medicine composition.
[0010] In some embodiments, the agent is suitable for PD of yang deficiency, wind generation, dampness, blood stasis and numbness type.
[0011] In some embodiments, the concentration of the agent is 1.2 to 4.8 g.mL -1 .
[0012] In some embodiments, the concentration of the agent is 4.8 g.mL -1 .
[0013] Compared with the prior art, the present invention has the following advantages:
[0014] 1. Rich human experience. The Chinese medicine composition applied for in the present invention is a modified version of four traditional Chinese medicine prescriptions recorded in "Treatise on Febrile and Miscellaneous Diseases" by Zhang Zhongjing in the late Eastern Han Dynasty, namely, Sini Decoction (Aconite, Dry Ginger, Licorice), Guizhi Fuzi Decoction without Gui and Baizhu Decoction (Aconite, Atractylodes, Licorice, Ginger, Jujube), Guizhi Jia Gegen Decoction (Cinnamon Twig, Peony, Gegen, Licorice, Ginger, Jujube), and Shengma Biejia Decoction without Realgar and Shujiao (Cimicifuga, Biejia, Angelica, Licorice), which are derived from ancient classic prescriptions and have a history of more than a thousand years of human experience.
[0015] 2. Guidance of TCM theory. The Chinese medicine composition applied for in the present invention is formulated based on the TCM pathogenesis theory of PD water cold soil damp wood depression and wind. Huang Yuanyu of the Qing Dynasty wrote in "Four Sacred Heart Sources": "The liver wood of Jueyin is born in kidney water and grows in spleen soil. When the water and soil are mild, the liver wood flourishes, the wood is quiet and the wind is calm; when the water is cold and the soil is damp, the wood qi cannot grow, then the wood is depressed... All diseases arise from the depression of wood qi." The kidney is the root of the body, the spleen is responsible for the circulation of qi, the liver is responsible for the release and ascending, and when all organs are harmonious, all diseases will not arise. The liver wood is born in kidney water and grows in spleen soil. When the water and soil are mild, the liver wood flourishes, the wood is quiet and the wind is calm. When the water is cold and the soil is damp, the wood qi cannot grow, then the wood is depressed and the wind arises. Wind and wood are the thieves of the five internal organs and the leader of all diseases. All diseases arise from the depression of wood qi. The kidney yang is prone to deficiency, and yang deficiency can cause internal coldness, making the kidney water prone to cold stagnation, the spleen earth prone to dampness, and the liver wood prone to stagnation. These three factors, water coldness, earth dampness, and wood stagnation, often interact with each other, resulting in a series of wind syndromes.
[0016] The disease location of PD is in the kidney (water), liver (wood), spleen (earth) and tendons. The disease is characterized by deficiency in the root and excess in the superficial. The deficiency is in the kidney yang, and the excess is in cold, dampness, blood stasis and wind. Cold water, damp earth and wood stagnation generate wind, and wind, cold, dampness and blood stasis block the tendons. The core pathogenesis is tendon spasm. ① The tendons regulate limb movement. The liver wood governs the tendons of the body. The normal function of the tendons depends on the warmth of yang and the nourishment of body fluid and blood. Kidney yang is the root of the body's yang energy. "The yang energy of the five internal organs cannot be developed without it" (Jingyue Complete Works). "Yang energy nourishes the spirit when it is refined and nourishes the tendons when it is soft. If it cannot open and close, cold air will follow it, and kyphosis will occur" (Suwen·Qi Sheng Tong Tian Lun). "Suwen·Zhi Zhen Yao Da Lun" records that "all wind-induced dizziness and vertigo belong to the liver", "all violent stiffness and stiffness belong to the wind", and "all cold contraction and retraction belong to the kidney". The liver and kidney have the same origin. If kidney yang is deficient, liver yang will also be deficient. If yang is deficient, internal cold will occur. On the one hand, cold contraction will stagnate tendons and veins, and tendons and veins will be tight. On the other hand, yang energy can promote the production of body fluid and blood. If yang energy is strong, the production of body fluid and blood will be sufficient. If yang energy is deficient, the production of body fluid and blood will be insufficient, and tendons and veins will not be nourished, which can easily cause PD movement symptoms such as internal wind limb tremor or muscle tightness. ② Yang energy transports substances such as body fluid and blood to tendons and veins through meridians to play a nutritional role. If dampness and blood stasis block the meridians, the transport of nutrients will be blocked, which will also aggravate the symptoms of limb tremor or muscle cramps. "Kan Yang is deficient and cannot promote Yi wood, and the warming qi is weakened, so wood is trapped and blood is stagnant" ("Four Sacred Heart Sources"). PD patients gradually lose liver and kidney yang qi, blood flows slowly, and stagnates to form blood stasis; kidney yang is deficient, the warming power is reduced, spleen yang loses warmth, fire cannot warm the earth, body fluid metabolism is abnormal, and fluid gathers over time to form dampness. Dampness and blood stasis block the meridians, the flow of body fluid and blood is stagnant, nutrients cannot be transported to the tendons and veins throughout the body, and the tendons and veins lose moisture, which aggravates limb tremor or muscle cramps. As "Lingshu·Xieke" says: "Evil qi hates blood, so it cannot stay. Staying will hurt the tendons and joints, and the organs cannot be flexed and extended, so it is cramped." "Suwen·Zhizhen Yaoda Lun" says that "all spasms and stiff necks are due to dampness."
[0017] 3. The prescription and medicine compatibility are rigorous. In the Chinese medicine composition of the present invention, aconite, dried ginger, and Morinda officinalis are the monarchs, which warm the kidney and dispel cold, targeting water cold; white atractylodes and Acanthopanax strengthen the spleen and dispel dampness, targeting earth dampness; angelica and turtle shell enter the liver meridian to activate blood circulation, and cinnamon twig enters the liver meridian to promote qi circulation, targeting wood depression, which are all ministers; gastrodia elata and centipede stop wind, targeting internal wind, as adjuvants; kudzu root, white peony root, and liquorice relax muscles, targeting muscle spasm and tightness, as messengers. The monarch, minister, assistant, and messenger cooperate with each other to achieve the effects of warming yang, stopping wind, removing dampness, and activating blood circulation, and are used to treat PD of yang deficiency, wind generation, dampness, stasis, and arthralgia.
[0018] 4. Definite clinical efficacy. The Chinese medicine composition of the present invention can significantly improve the motor symptoms and non-motor symptoms of PD patients with yang deficiency-induced wind and dampness-stasis-blocking type, reduce the daily dosage of levodopa equivalent dose of Western medicine, reduce the toxic and side effects of Western medicine, reduce the degree of dependence on Western medicine, delay the progression of PD disease, and has the effect of increasing efficacy and reducing toxicity.
[0019] 5. The mechanism of action is clear. The Chinese medicine composition applied for in the present invention can improve motor dysfunction in PD mice, regulate metabolic disorders in the biosynthesis pathways of phenylalanine, tyrosine and tryptophan, increase the activity of mitochondrial respiratory chain complexes I to IV, improve mitochondrial energy metabolism, promote ATP production and DA synthesis, reduce the loss of dopamine neurons in the substantia nigra of the midbrain, and has a neuroprotective effect. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 This is the open field motion trajectory diagram.
[0021] Figure 2 The effect of Panin I on the activity of substantia nigra neurons in the midbrain of PD mice. Note: Compared with the normal group, **** P﹤0.0001; compared with the model group, ## P﹤0.01, #### P﹤0.0001;n=5.
[0022] Figure 3 The effect of Panin I prescription on the content of DA and its metabolites and DAT in the striatum of PD mice. Note: Compared with the normal group, **** P﹤0.0001; compared with the model group, # P﹤0.05, ## P﹤0.01, ### P﹤0.001, #### P﹤0.0001;n=5.
[0023] Figure 4 The effect of Panin I prescription on TH expression in substantia nigra of PD mice. Note: Compared with the normal group, **** P﹤0.0001; compared with the model group, # P﹤0.05, ## P﹤0.01, ### P﹤0.001, #### P﹤0.0001; n=3 or 5.
[0024] Figure 5 The effect of Panin I on the morphological structure of mitochondria in substantia nigra neurons of PD mice. Note: Compared with the normal group, ** P﹤0.01, *** P﹤0.001; compared with the model group, # P﹤0.05; ## P﹤0.01;n=3.
[0025] Figure 6 The effect of Panin I prescription on mitochondrial ATP content, NAD+ / NADH, and ADP / ATP ratio in substantia nigra of PD mice. Note: Compared with the normal group, ****P<0.0001; compared with the model group,### P < 0.001, #### P<0.0001; n=5.
[0026] Figure 7 The effect of Panin I on the activity of nigral complexes Ⅰ-Ⅳ in PD mice. Note: Compared with the normal group, **P<0.01; ****P<0.0001, compared with the model group, ### P < 0.001, #### P<0.0001; n=5.
[0027] Figure 8 The effects of Panin No. 1 prescription on serum metabolites and metabolic pathways in PD mice. Note: A. OPLS-DA score; B. Venn diagram; C. Clustering heat map of differential metabolites; D. Metabolic pathway enrichment map; n = 5.
[0028] Fig. 9 This is a heat map of the correlation between serum differential metabolites and behavioral, morphological and mitochondrial energy metabolism indicators (fold change of the top 30), Note: *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. DETAILED DESCRIPTION
[0029] In the description of the present invention, it should be noted that, if the specific conditions are not specified in the examples, the experiments were carried out according to conventional conditions or the conditions recommended by the manufacturer. The reagents or instruments used, if the manufacturer is not specified, are all conventional products that can be purchased commercially.
[0030] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments.
[0031] Example 1
[0032] Animal experiment: In order to preliminarily explore the pharmacodynamic and pharmacological mechanism of Panin I prescription (the Chinese medicine composition applied for by the present invention, hereinafter referred to as Panin I prescription) in treating PD, the present invention replicated the PD model mice induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), and gave gradient doses of Panin I prescription and its positive control drug Madopar intervention, and conducted behavioral, morphological, substantia nigra mitochondrial energy metabolism and serum metabolomics tests. The specific experimental report is as follows:
[0033] 1. Animals
[0034] 80 healthy male SPF grade C57 / BL6 mice, with a body weight of (18.0-22.0) g, were purchased from Hunan Slake Jingda Experimental Animal Co., Ltd., with animal certificate: 430727231102163668. They were kept in the Animal Experiment Center of Hunan Normal University School of Medicine [Laboratory License: SYXK (Xiang) 2020-0012], with living environment: 5 mice per cage, sufficient food and water, room temperature of 24-26 ° C, constant humidity, humidity of 51%-55%, circadian light rhythm, light / dark cycle of 12h / 12h. The animal experiment protocol was reviewed and approved by the Experimental Animal Ethics Committee of Hunan Normal University School of Medicine (Ethics Number: D2023027).
[0035] 2. Methods
[0036] 2.1 Drugs and reagents
[0037] Paning I prescription composition: 9g of aconite root (processed aconite root), 9g of angelica root, 15g of Morinda officinalis, 15g of Atractylodes macrocephala, 15g of Gastrodia elata, 5g of Scolopendra subspinipes, 9g of dried ginger, 15g of Acanthopanax senticosus, 15g of Carapace of Turtle, 15g of Pueraria root, 15g of Cinnamon twig, 15g of White Peony Root, 9g of Licorice root (roasted Licorice root). According to the method for converting equivalent doses of drugs between humans and experimental animals (based on the ratio of the body surface area of the standard body weight of 20g mice and 70kg humans), the clinical equivalent dose of Paning I prescription is calculated to be 18.1g·kg -1 ·d -1 The medium dose was used as the high and low doses, which were twice the clinical equivalent dose (36.2 g kg -1 ·d -1 ), 0.5 times (9.05 g kg -1· d -1 The traditional method of boiling the medicine was used to concentrate the medicine to 2.4 g mL in the medium-dose group. -1 , high dose group 4.8g·mL -1 , low dose group 1.2 g·mL -1 , and store in a 4℃ refrigerator for later use.
[0038] Madopar (specification: L-dopamine) 200 mg: (benserazide) 50 mg, purchased from Shanghai Roche Pharmaceuticals Co., Ltd., drug batch number: YT0258, based on the clinical maintenance dose and the equivalent dose conversion method for humans and experimental animals (based on the body surface area ratio of the standard body weight of mice 20 g and humans 70 kg), it was calculated that the daily dose of Madopar required for mice was 97.5 mg kg -1 The tablets were ground into powder and dissolved in 0.9% sodium chloride injection to prepare a Madopar solution with a concentration of 9.75 mg mL -1, and stored in a 4℃ refrigerator for later use. MPTP was purchased from Beijing Solebow Technology Co., Ltd., item number: M7450. 30 mg kg -1 ·d -1 According to the drug concentration and dosage, MPTP was dissolved in 0.9% sodium chloride injection and shaken to a concentration of 3 mg mL -1 , and store in a 4℃ refrigerator for later use.
[0039] 2.2 Grouping, modeling and drug administration
[0040] After 3 days of motor behavior training, 80 C57 / BL6 male mice were weighed and then numbered according to weight from light to heavy. SPSS25.0 generated random numbers and randomly divided them into a normal group of 10 mice and a modeling group of 70 mice. MPTP (30 mg kg -1 ), and a chronic model was created, once every 3 days, for a total of 10 times, and the normal group was given an equal amount of normal saline intraperitoneal injection. After the 6th intraperitoneal injection, the mice were scored for modeling, and 63 mice out of 70 mice were successfully modeled. Subsequently, 50 mice with successful modeling were selected according to the above random grouping method and divided into a model group, a Madopar group, and a low-, medium-, and high-dose group of Panin I, with 10 mice in each group. After the 6th intraperitoneal injection, oral administration was started for 14 consecutive days.
[0041] The mice were evaluated for modeling after the sixth intraperitoneal injection. Similar to normal mice, no symptoms were scored as 0 points; 1 point was scored for erect hair, arched back, intermittent fine tremors, but free movement; 2 points were scored for frequent tremors, slow movements, trembling tails, and gradually limited movement; 3 points were scored for continuous tremors, obvious slow movements, erect tails, stiff limbs, and obvious limited movement; 4 points were scored if the mice were in a dying state or died due to general paralysis and convulsions. A score of 2 to 3 points indicated that the modeling was successful.
[0042] 2.3 Specimen sampling and processing
[0043] Motor function was evaluated on days 0, 3, 6, 9, and 12 after the first oral gavage. On the second day after the end of the administration of all mice, the mice were anesthetized with isoflurane and the mouse serum was taken for non-targeted metabolomics detection. Then the chest was opened and the right atrial appendage was perfused and rinsed with 0.9% sodium chloride solution. A part of the substantia nigra of the midbrain was cut and stored in tissue culture medium for transmission electron microscopy observation and chemiluminescence detection. A part of the substantia nigra and striatum was stored in dry ice for ELISA and immunoblotting detection; the other part was perfused with 4% paraformaldehyde, and the whole brain was retained for immunohistochemistry and Nissl staining (Nissl) detection.
[0044] 2.4 Detection indicators and methods
[0045] 2.4.1 Motor function evaluation
[0046] The open field test, rotarod test and cylinder test were used to evaluate the motor function of PD mice.
[0047] ① Open field experiment: A homemade open field was used. The open field equipment consisted of 16 squares of 10 cm × 10 cm × 10 cm. Before the experiment, the mice were placed in the middle square of the open field to adapt for 5 minutes. After the adaptation, a video recorder was used to record the movement trajectory of the mice in the open field for 3 minutes and the number of squares crossed. The movement trajectory of the mice was then analyzed using the Traker software. To prevent the smell and excrement of mice from interfering with subsequent mouse detection, the open field box was wiped with alcohol before the mice were rotated.
[0048] ②Rotaro test: Before the formal experiment, the mice were placed on the rotarod and trained to run for 3 consecutive days at a constant speed of 4r / min, 3 times a day, with an interval of 15min each time. The mice that could not persist on the rotarod for at least 60s were eliminated. In the formal experiment, the mice were placed on the rotarod instrument for accelerated exercise, with a speed of 4r / min to 40r / min within 300s. The rotarod instrument automatically recorded the duration of each mouse from the start of the experiment to falling off the machine.
[0049] ③ Cylinder experiment: During the experiment, the mice were placed in a glass cylinder (with an outer diameter of 89 mm and a height of 120 mm). A video recorder was placed directly above the cylinder to record the exploratory behavior of the mice's upper limbs for 3 minutes and count the number of times one or both forelimbs touched the wall.
[0050] 2.4.2 Nissl staining to detect neuronal activity in substantia nigra
[0051] ① Bake the slices at 60℃ for 12h, ② Dewax the slices to water: first place the slices in xylene for 10min×2 times. Then place them in 100%, 100%, 95%, 85% and 75% ethanol for 5min each. Then rinse with distilled water for 5min; ③ Stain with Nissl dye for 0.5~1min, depending on the depth of staining; ④ Wash away the floating color with distilled water; ⑤ Differentiation solution (1% glacial acetic acid) differentiates until the background is colorless under the microscope, and the cells and Nissl bodies have clear outlines; ⑥ Seal the slices with buffered glycerol and observe under a microscope.
[0052] 2.4.3ELISA detection of DA and its metabolites and dopamine transporter (DAT) content in mouse striatum
[0053] Wash the mouse striatum to remove blood stains, cut into small pieces to make homogenate, centrifuge the tissue homogenate at 5000g for 5 minutes at 2-8℃, take the supernatant, take an appropriate amount of supernatant, and use DA, 3-methoxy 4-hydroxyphenylacetic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC) and DAT kit for detection. The operation steps are as follows: ① Move various reagents to room temperature for 30 minutes, configure reagents according to the above method, and set aside. ② Add samples: set up blank wells, standard wells and sample wells to be tested respectively. No solution is added to the blank wells, and 50μL of standard or sample to be tested is added to each of the remaining wells, and then 50μL of biotin marker working solution is added. Mix thoroughly, cover with a new plate sticker, and incubate at 37℃ for 30 minutes. ③ Discard the liquid in the well, spin dry, and wash the plate 3 times. Soak for 2 minutes each time, 200μL per well, spin dry. ④ Add 100μL of horseradish peroxidase-labeled avidin working solution (no addition to blank wells), mix thoroughly, cover with a new plate sticker, and incubate at 37℃ for 30 minutes. ⑤ Discard the liquid in the wells, spin dry, and wash the plate 5 times. Soak for 2 minutes each time, 200μL per well, spin dry. ⑥ Add 90μL of substrate solution to each well, shake and mix, and color at 37℃ in the dark for 20 minutes. ⑦ Add 50μL of stop solution to each well in sequence to terminate the reaction. ⑧ Measure the optical density (OD value) of each well in sequence at a wavelength of 450nm within 5 minutes after the reaction is terminated using an enzyme reader.
[0054] 2.4.4 Immunoblotting to detect tyrosine hydroxylase (TH) protein expression in substantia nigra
[0055] ① Extract protein: Cut 0.025g of substantia nigra tissue, wash the tissue with ice-cold PBS, add lysis buffer and grind the tissue repeatedly in a biological sample homogenizer until the tissue blocks are no longer visible, then lyse on ice for 10min and centrifuge for 15min. Transfer the supernatant to a 1.5mL centrifuge tube. Take 200uL of protein supernatant, add 50uL of 5× loading buffer and mix well, boil in boiling water for 5min, and put it in an ice box for medium-speed cooling for standby use; ② Electrophoresis: According to the results of protein quantification, 2uL of marker is added to the first well, and 10~20uL of denatured protein is loaded in each well of the other wells. Start electrophoresis (130min, 75V), and stop electrophoresis when bromophenol blue electrophoresis reaches the bottom of the gel. ③ Cut gel, transfer membrane, and block: Cut the prepared gel according to the molecular weight, then put the NC membrane and filter paper into the transfer buffer and completely soak them, then put the filter paper, NC membrane, and gel in order, without bubbles in the middle, cover the instrument, and start transfer membrane (300mA constant current). After completion, take out the membrane and wash it once in 1×PBST, then soak it in 5% skimmed milk powder prepared with 1×PBST at room temperature for 90 minutes; ④ Antibody incubation: Incubate the membrane with TH antibody or β-actin antibody (1:5000) (overnight at 4°C, and place it at room temperature for 30 minutes the next day). After incubation, wash it 3 times with 1×PBST, 15 minutes each time. Then incubate with HRP-labeled Goat anti-Rabbit IgG secondary antibody (1:5000, room temperature, 90 minutes). ⑤ Color development and exposure: Incubate the membrane with ECL chemiluminescent solution for 1 minute, absorb the liquid with filter paper, wrap the hybridization membrane with plastic film, and image it with a gel imaging system. ⑥ Use quantity one professional grayscale analysis software to perform relative quantitative analysis on the exposed film.
[0056] 2.4.5 Immunohistochemical detection of TH protein expression in substantia nigra
[0057] The brain tissue was fixed in 4% paraformaldehyde. The operation steps are as follows: ① Place the tissue slices in a 60℃ oven for 12h. ② Dewax the slices to water: Place the slices in xylene 3 times, 20min each time. Then place them in 100%, 95%, 85% and 75% ethanol for 5min each. Then rinse with distilled water for 5min. ③ Heat repair antigen: Immerse the slices in citrate buffer and heat them in a microwave oven until boiling, then turn off the power and cool to room temperature. Then wash with 0.01M PBS 3 times, 3min each time. ④ Add 1% periodic acid at room temperature for 10min to inactivate endogenous enzymes. Then rinse with PBS 3 times, 3min each time. ⑤ Incubate the primary antibody: Add appropriately diluted TH antibody (1:5000) and incubate at 4℃ overnight. Rinse with PBS 3 times, 5min each time. ⑥ Incubate with secondary antibody: add 50μL anti-rabbit-IgG antibody-HRP polymer, incubate for 30min at 37℃, rinse with PBS 3 times, 5min each time. ⑦ DAB color development: add 50μL pre-made DAB working solution for color development, incubate at room temperature for 3min, control the reaction time under the microscope, and then wash with distilled water; ⑧ Rinse with distilled water after 5-10min hematoxylin counterstaining, and then return to blue with PBS; ⑨ Dehydrate with different levels of alcohol (60%-100%) for 5min. After taking out, place in xylene twice, 10min each time, seal with neutral gum and observe under a microscope. ⑩ Use Image J image analysis software to calculate the TH mean optical density (MOD) value for relative quantitative analysis.
[0058] 2.4.6 Transmission electron microscopy observation of mitochondrial morphology of substantia nigra dopamine neurons
[0059] ① Material fixation: cut 1mm 3② Post-fixation: Fix with 1% osmium acid in dark place at room temperature for 2 hours. Then rinse with 0.1M phosphate buffer PBS (PH 7.4) 3 times, 15 minutes each time. ③ Dehydration at room temperature: Dehydrate the tissue in alcohol of different concentrations (30%, 50%, 70%, 80%, 95%, 100%, 100%) for 20 minutes, and then put it in 100% acetone twice, 15 minutes each time. ④ Infiltration embedding: Pour pure 812 embedding agent into the embedding plate, then insert the sample into the embedding plate, adjust the oven to 37℃, and leave overnight. ⑤ Polymerization: Adjust the oven to 60℃, place the embedding plate in it, polymerize for 48 hours, and then take out the resin block for use. ⑥Ultrathin sections: Use an ultrathin slicer to cut the resin block into ultrathin sections of 60-80 nm, and use a 150-mesh square copper mesh to fish out the sections. ⑦Staining: Use a 2% uranyl acetate saturated alcohol solution to stain the copper mesh in the dark for 8 minutes; then wash it with 70% alcohol for 3 times, and then wash it with ultrapure water for 3 times; place the copper mesh in a 2.6% lead citrate solution, avoid carbon dioxide, and stain it for 8 minutes; wash it with ultrapure water again for 3 times, and after the filter paper is slightly dried, place the copper mesh sections in a copper mesh box and dry them at room temperature overnight. ⑧ Observe the copper mesh sections under a transmission electron microscope and collect images. ⑨ Use Image J image analysis software to outline the mitochondria with clear outlines, and calculate the average cross-sectional area and average cross-sectional perimeter of the mitochondria.
[0060] 2.4.7 Chemiluminescence method for detecting ATP content in substantia nigra
[0061] ① Weigh 0.05g of substantia nigra sample and place it in a 2mL EP tube, then add 0.45mL of reagent 1 to the tube, grind at a frequency of 60Hz for 90s in an ice water bath to make a tissue homogenate, then place in a boiling water bath for 2min, cool with running water, centrifuge at 10000g for 10min, and place the supernatant on ice for testing. ② Take 100μL of enzyme working solution and add it to the standard well and the assay well respectively, and let it stand for 5min. ③ Add 100μL of standard products of different concentrations and 100μL of the supernatant of the sample to be tested to the standard well and the assay well in ②, respectively, and quickly mix with a pipette. ④ Measure the fluorescence value of each well on the chemiluminescence detector.
[0062] 2.4.8 Chemiluminescence detection of ADP / ATP content in substantia nigra mitochondria
[0063] ① The sample preparation steps are the same as 2.4.7. ② Add ATP working solution to the 96-well plate and shake to mix. ③ Place the plate in the microplate reader and let it stand for a while. ④ Detect the luminescence value. ⑤ Prepare ADP working solution and detect the luminescence value before adding. ⑥ Add ADP working solution to each well and shake to mix. ⑦ Place the plate in the microplate reader again and let it stand for a while. ⑧ Detect the luminescence value. ⑨ Calculate the ADP / ATP ratio based on the detected luminescence value.
[0064] 2.4.9 Chemiluminescence detection of NAD+ / NADH content in substantia nigra mitochondria
[0065] ① Preparation of NADH standard: Use 655μL NADH preparation solution to dissolve 5mg NADH to obtain 10mM NADH standard. ② Determination of NAD+ / NADH content or ratio: Take the sample to be tested in a centrifuge tube and heat it at 60℃ for 30min to decompose NAD+. If there is insoluble matter, centrifuge and take the supernatant to a 96-well plate, and measure the fluorescence value of each well on a chemiluminescence detector. Data calculation: Calculate the average absorbance of each point in the standard group, subtract the absorbance of the blank control group, and obtain the absorbance of each standard. Draw a standard curve (with NADH concentration as the horizontal axis and absorbance as the vertical axis). Calculate the total concentration of NAD+ and NADH or the concentration of NADH in the sample according to the standard curve. When not heated, the detection result is NADtotal; after heating, the detection result is the concentration of NADH. According to the concentration and sample volume detected, calculate the amount of NAD+, NADH, NADtotal and the ratio of NAD+ / NADH. [NAD+]=[NADtotal]-[NADH][NAD+] / [NADH]=([NADtotal]-[NADH]) / [NADH].
[0066] 2.4.10 Chemiluminescence detection of the activity of mitochondrial respiratory chain complexes (I, II, III, IV) in substantia nigra
[0067] ① Take the substantia nigra tissue of mice and rinse it twice in mitochondrial separation buffer, cut it into pieces, and transfer it to a glass homogenizer for homogenization. ② Transfer the homogenate to a centrifuge tube and centrifuge it at 4℃ and 600g for 10min. Transfer the supernatant to a new tube, resuspend the precipitate with mitochondrial separation buffer, and continue to grind it on ice. ③ Centrifuge the homogenate at 4℃ and 600g for 10min, and mix the supernatant with the supernatant collected last time. ④ Centrifuge the mixed solution at 4℃ and 11000g for 15min. The supernatant is the cytoplasmic component and the precipitate is the crude mitochondrial extract. ⑤ Resuspend the precipitate in 1.5mL of 15% percoll solution and carefully transfer it to the 25% and 40% percoll gradient solution with a pipette. ⑥ Centrifuge at 15000g for 10min. An extract band appears above the interface of 25% and 40% percoll solutions, which is the purified mitochondria. Transfer the extract to a new tube with a pipette, add mitochondrial storage buffer, mix, centrifuge at 11000g for 15min, collect the precipitate, and suspend it in mitochondrial storage buffer. According to the kit instructions, the activities of respiratory chain complexes I, II, III, and IV were determined by spectrophotometry in standard buffer at 30°C.
[0068] 2.4.11 Detection of serum differential metabolites using UHPLC-Q-TOF / MS non-targeted metabolomics technology
[0069] ① Sample preparation: methanol / acetonitrile extraction method, after the serum was slowly thawed at 4℃, 100uL was taken, 400uL pre-cooled methanol / acetonitrile / water solution (2:2:1, v / v) was added, vortexed, low-temperature ultrasonic for 30min, -20℃ for 30min, centrifuged at 14000g for 20min, the supernatant was taken, vacuum dried, and 100μL acetonitrile aqueous solution (acetonitrile: water = 1:1, v / v) was added for re-dissolution during mass spectrometry analysis, vortexed, and centrifuged at 14000g for 15min at 4℃. The supernatant was taken for sampling and analysis.
[0070] ②Chromatographic analysis: Agilent 1290Infinity LC ultra-high performance liquid chromatography system (UHPLC) HILIC column was used to separate the samples. Experimental conditions: column temperature 25℃, flow rate 0.5mL / min, injection volume 2μL. Mobile phase: phase A is water + 25mM ammonium acetate + 25mM ammonia water, phase B is acetonitrile. Gradient elution program: In the initial stage (0-0.5min), phase B accounts for 95%; then (0.5-7min), phase B decreases to 65%; then (7-8min), phase B further decreases linearly to 40%; during (8-9min), phase B remains unchanged at 40%; then (9-9.1min), phase B again increases linearly from 40% to 95%; finally (9.1-12min), phase B remains at 95% until the end of the analysis. During the entire analysis process, the samples were properly stored in an autosampler at 4℃. The samples were analyzed continuously in a randomized order to eliminate the influence of signal fluctuations. Quality control (QC) samples were inserted regularly to monitor and evaluate the stability of the system and the reliability of the experimental data in real time.
[0071] ③Mass spectrometry identification: AB Triple TOF 6600 mass spectrometer was used to collect the primary and secondary spectra of the samples. After separation by Agilent 1290 Infinity LC ultra-high performance liquid chromatography system (UHPLC), the samples were analyzed by mass spectrometry using Triple TOF 6600 mass spectrometer (ABSCIEX), and electrospray ionization (ESI) positive ion and negative ion modes were used for detection. The ESI source setting parameters are as follows: nebulizer gas auxiliary heating gas 1 (Gas1): 60, auxiliary heating gas 2 (Gas2): 60, curtain gas (CUR): 30psi, ion source temperature: 600℃, spray voltage (ISVF) ±5500V (positive and negative modes); primary mass-to-charge ratio detection range: 60-1000Da, secondary product ion mass-to-charge ratio detection range: 25-1000Da, primary mass spectrometry scanning accumulation time: 0.20s / spectra, secondary mass spectrometry scanning accumulation time 0.05s / spectra; the secondary mass spectrum was obtained using the data-dependent acquisition mode (IDA), and the peak intensity value screening mode was adopted, declustering voltage (DP): ±60V (positive and negative modes), collision energy: 35±15eV, IDA settings are as follows: dynamic exclusion of isotope ion range: 4Da, 10 fragment spectra are collected for each scan.
[0072] 2.4.12 Statistical methods
[0073] Graphpadprism10.0 software was used to analyze the experimental data, and the quantitative data were expressed as mean ± standard deviation. One-way analysis of variance was used for comparison among multiple groups. If the variances were equal, the LSD method was used for pairwise comparisons. If the variances were unequal, the Tambane's T2 method was used for pairwise comparisons. P < 0.05 was considered statistically significant.
[0074] For non-targeted metabolomics data, ProteoWizard software was used to convert them into .mzXML format, and then XCMS software was used for peak alignment, retention time correction, and peak area extraction. Serum metabolites were analyzed based on secondary fragments, mass-to-charge ratio (m / z), and isotope distribution using the HMDB database. Supervised orthogonal partial least squares discriminant analysis (OPLS-DA) was used to determine the stability and differences between samples. Then, the VIP value and t-test were combined to screen the differential metabolites between groups. Finally, MetaboAnalyst5.0 (https / / www.metaboanalyst.ca / ) and KEGG database (https / / www.kegg.jp / ) were used to perform pathway enrichment analysis on differential metabolites; Spearman correlation analysis was used to analyze the correlation between serum differential metabolites and dopamine neuron pathological biochemistry and mitochondrial energy metabolism indicators. R software was used to draw a heat map for visualization of differential metabolites and Spearman correlation coefficients.
[0075] 3. Results
[0076] 3.1 Effect of Panin I on the motor function of PD mice
[0077] The open field test, rotating rod test, and cylinder test can reflect the motor function of mice. Figure 1 As shown in the figure, compared with the normal group, the movement distance and the time spent on the rotating rod in the model group were significantly shortened, the spontaneous movement of the upper limbs decreased, and the motor function became worse with the increase in the number of intraperitoneal injections, and the difference was statistically significant (P﹤0.05); compared with the model group, the motor function of each drug-administered group improved on the 12th day after intragastric administration, and the difference was statistically significant (P﹤0.05). This shows that Panin I can improve the motor function of PD mice.
[0078] Table 1 Effects of Paning I prescription on motor function of PD mice ( n=10)
[0079]
[0080] Note: Compared with the normal group, * P﹤0.05; compared with the model group, # P﹤0.05
[0081] 3.2 Effect of Panin I on the activity of substantia nigra neurons in PD mice
[0082] like Figure 2 As shown in the figure, in the normal group, the neuronal cells in the substantia nigra region were full in morphology, closely distributed and arranged, and presented purple-light blue color; compared with the normal group, the neuronal cells in the model group were shrunken in morphology, sparsely distributed, scattered in arrangement, and even had cell shrinkage; the average optical density of neurons decreased, and the difference was statistically significant (P﹤0.01); compared with the model group, the neuronal cell morphology of each drug-treated group was improved, and the number increased; the average optical density of neurons in the medium- and high-dose groups and the Madopar group increased, and the difference was statistically significant (P﹤0.01). This shows that Panin I can reduce the loss of dopamine neurons in the substantia nigra of the midbrain and has a protective effect on the substantia nigra neurons of PD mice.
[0083] 3.3 Effects of Panin I on the content of DA and its metabolites and DAT in the striatum of PD mice
[0084] The content of striatal DA is positively correlated with the number of neurons. DOPAC and HVA are DA metabolites. DAT is a DA neuron cell membrane protein that can maintain the homeostasis of DA inside and outside neurons. Figure 3 Compared with the normal group, the content of DA, DOPAC, HVA and DAT in the model group decreased, and the difference was statistically significant (P﹤0.0001); compared with the model group, the content of DA, HVA and DAT in the Madopar group and the high-dose group increased, and the difference was statistically significant (P﹤0.05); the content of DOPAC in the Madopar group and the medium- and high-dose groups increased, and the difference was statistically significant (P﹤0.01). This shows that Panin I can promote the synthesis of DA in the brain.
[0085] 3.4 Effect of Panin I on TH expression in substantia nigra of PD mice
[0086] like Figure 4 As shown in the figure, TH is mainly expressed in the cytoplasm, with positive staining in yellow or brownish yellow, and evenly stained in darker cases. Compared with the normal group, the average optical density of TH in the model group decreased, and the difference was statistically significant (P﹤0.0001). Compared with the model group, the average optical density of TH in the Madopar group and the high-dose group increased, and the difference was statistically significant (P﹤0.01). The results of immunoblotting were consistent with those of immunohistochemistry ( Figure 4 ). This indicates that Panin I can reduce the loss of dopamine neurons in the substantia nigra of the midbrain and has a protective effect on the substantia nigra neurons of PD mice.
[0087] 3.5 Effect of Panin I on the morphological structure of mitochondria in the substantia nigra of PD mice
[0088] like Figure 5As shown in the figure, the mitochondrial morphology of the substantia nigra neurons of the normal group mice was normal, the inner cristae were abundant and clearly visible, the arrangement was dense, and the double membrane structure was clear; compared with the normal group, the mitochondria in the model group were swollen, the mitochondria were fused and obviously vacuolated, the cristae were reduced or even disappeared, and the double membrane structure was blurred; the average cross-sectional area and average cross-sectional perimeter increased, and the difference was statistically significant (P﹤0.01); compared with the model group, the mitochondrial morphology of each drug-treated group was improved, among which the average cross-sectional area of mitochondria in the Madopar group and the high-dose Chinese medicine group was significantly reduced, and the difference was statistically significant (P﹤0.01); the average cross-sectional perimeter of mitochondria in the Madopar group and the medium- and high-dose Chinese medicine groups was reduced, and the difference was statistically significant (P﹤0.05). This shows that Panin I can protect the ultrastructure of mitochondria in the substantia nigra dopaminergic neurons and has a protective effect on the substantia nigra neurons of PD mice.
[0089] 3.6 Effect of Panin I on ATP content in substantia nigra of PD mice
[0090] Results Figure 6 A. Compared with the normal group, the ATP content in the model group was significantly reduced, and the difference was statistically significant (P﹤0.0001); compared with the model group, the ATP content in each drug-treated group increased to varying degrees, among which the Madopar group and the medium- and high-dose Chinese medicine group increased significantly, and the difference was statistically significant (P﹤0.001). This suggests that Panin I can promote the generation of ATP in the substantia nigra and promote energy metabolism.
[0091] 3.7 Effect of Panin I on the ADP / ATP content of mitochondria in substantia nigra of PD mice
[0092] The results are shown in Figure Figure 6 B. The ADP / ATP ratio can directly reflect the integrity of mitochondrial function. The higher the ADP / ATP ratio, the more unconverted ADP remains and the less ATP is generated, leading to mitochondrial function damage. Compared with the normal group, the ADP / ATP ratio of the model group was significantly increased (P<0.0001); compared with the model group, the ADP / ATP ratio of each drug-treated group was significantly decreased (P<0.001). This suggests that Panin I can improve the degree of brain mitochondrial damage in PD mice by reducing the ADP / ATP ratio.
[0093] 3.8 Effect of Panin I on the NAD+ / NADH content of mitochondria in the substantia nigra of PD mice
[0094] NAD+ and its reduced form NADH are important cofactors in redox metabolism and signal transduction in all forms of life. They are the core of metabolic pathways such as glycolysis, tricarboxylic acid cycle, and oxidative phosphorylation. The NAD+ / NADH ratio of each group of mice was measured to evaluate the energy efficiency of the mitochondrial respiratory chain. Figure 6C, Compared with the normal group, the NAD+ / NADH ratio in the model group was significantly decreased (P<0.0001); the NAD+ / NADH ratio in the high-dose Chinese medicine group and the dopamine group was significantly increased (P<0.001). This suggests that Panin I can improve the efficiency of mitochondrial electron respiratory chain production by improving the NAD+ / NADH ratio in PD mice.
[0095] 3.9 Effect of Panin I on the activity of respiratory chain complexes I to IV in substantia nigra mitochondria of PD mice
[0096] The respiratory chain complex on the inner membrane of mitochondria releases energy by transferring electrons and is a key enzyme in the energy metabolism process. Figure 7 Compared with the normal group, the activity of brain mitochondrial complex I-IV in the model group was significantly reduced (P<0.01 or P<0.0001); the activity of brain mitochondrial complex I-IV in the mice in each drug group increased to varying degrees, among which the expression of high-dose Chinese medicine group and Madopar group was significantly upregulated (P<0.05 or P<0.01 or P<0.001). This suggests that Panin I can increase the activity of mitochondrial respiratory chain complexes and promote mitochondrial energy metabolism.
[0097] 3.10 Effects of Panin I on serum metabolites and metabolic pathways in PD mice
[0098] Changes in PD serum metabolites are closely related to the mitochondrial energy metabolism of dopaminergic neurons in the brain. In order to characterize the effect of Panin I on the expression of serum metabolites in PD mice, we used UHPLC-Q-TOF / MS technology to determine the comprehensive metabolic profile of mouse serum. Figure 8 As shown in A, there was a clear separation of metabolites among the three groups, indicating that PD mice had significant metabolic disorders, which were partially restored by intervention with Panin I prescription.
[0099] We screened for significantly different metabolites by combining the positive ion mode data with the negative ion mode data. Based on the screening conditions VIP>1.0 and P<0.05, 144 significantly different metabolites (89 upregulated and 55 downregulated) were identified between the normal group and the model group ( Figure 8 B). In addition, 271 significantly different metabolites (159 up-regulated and 112 down-regulated) were screened out between the high-dose group and the model group of Panin I prescription ( Figure 8 B). Among them, 40 common differential metabolites were obtained ( Figure 8 B).
[0100] In order to more clearly show the changing trends of differential metabolites between groups, we performed cluster analysis on the 40 significantly differential metabolites obtained and established a hierarchical clustering heat map. Figure 8As shown in C, the degree of change of differential metabolites in the high-dose group of Panin I and the normal group were close to each other, and there was a trend of separation from the model group.
[0101] In order to explore the functions of differential metabolites, we performed pathway enrichment analysis on 40 significantly differential metabolites using MetaboAnalyst 5.0 and the KEGG database. Figure 8 As shown in Figure D, there are four metabolic pathways that are enriched: aminoacyl-tRNA biosynthesis, amino acid biosynthesis, galactose metabolism, and phenylalanine, tyrosine and tryptohan biosynthesis. Among them, the biosynthesis metabolic pathways of phenylalanine, tyrosine and tryptohan are the most enriched.
[0102] 3.11 Potential relationships between serum differential metabolites and behavioral, morphological, and mitochondrial energy metabolism indices
[0103] In order to further explore the potential relationship between the changes in serum metabolites of PD mice after treatment with Panin I prescription and the pathological biochemistry of dopamine neurons (Nissl, TH, DA, HVA, DOPAC, DAT) and mitochondrial energy metabolism (mitochondrial complexes I to IV, ATP, ADP / ATP, NAD+ / NADH). We performed Spearman correlation analysis on the above indicators and 30 serum differential metabolites. Fig. 9As shown, α-linolenic acid (2-linoleoylglycerol), 1-oleoyl-l-.alpha.-lysophosphatidic acid (1-oleoyl-l-.alpha.-lysophosphatidic acid), α-ketoisovaleric acid (Alpha-ketoisovaleric acid), DL-tyrosine (DL-tyrosine), 8z, 14z-eicosadienoic acid (8z, 14z-eicosadienoic acid), 17-octadecynoic acid (17-octadecynoic acid), DL-2-aminocaprylic acid (DL-2-Aminooctanoic acid), Linoleic acid (Linoleic acid), Ricinoleic acid (Ricinoleic acid), Erucic acid (Erucic acid Fourteen differential metabolites, including 1,4-dihydroxybenzene, 1,4-dihydroxybenzene, 3-methoxy-4-hydroxyphenylglycolsulfate, and o-phenylenediamine, were positively correlated with various dopamine neuron pathological biochemical and mitochondrial energy metabolism indices (P<0.05), and were significantly correlated with caffeine, L-Anserine, D-gluconate, gamma-L-Glutamyl-L-phenylalanine, methionine sulfoxide, indole-3-butyric acid, diphenylamine, 1,4-dihydroxybenzene, DL-2-aminoadipic acid, trimethylamine n-oxide, and 1,4-dihydroxybenzene. The results showed that 16 metabolites, including sulfamethoxazole, sulfamethoxazole, tetradecylamine, etc., were negatively correlated with various dopamine neuron pathological biochemistry and mitochondrial energy metabolism indicators (P<0.05). This showed that Panin No. 1 prescription could affect mitochondrial energy metabolism by regulating serum metabolites, promoting ATP production, reducing the loss of dopamine neurons in the substantia nigra of the midbrain, and promoting DA synthesis, thereby playing a role in treating PD.
[0104] 4. Conclusion
[0105] 4.1 Panin I prescription can improve motor dysfunction in PD mice, reduce the loss of dopaminergic neurons in the substantia nigra of the midbrain, increase the expression of DA and its metabolites, DAT, and has a neuroprotective effect.
[0106] 4.2 Panin I can increase the activity of mitochondrial respiratory chain complexes I to IV, promote ATP production, and improve mitochondrial energy metabolism.
[0107] 4.3 Panin I can regulate metabolic disorders in the biosynthesis pathways of phenylalanine, tyrosine and tryptophan and improve mitochondrial energy metabolism.
[0108] Example 2
[0109] Clinical study: To further evaluate the clinical efficacy and safety of Panin I prescription in treating PD of yang deficiency-induced wind and dampness-stasis type, the present invention adopts the method of real-world research, combines Panin I prescription with conventional Western medicine treatment, and observes TCM syndrome, motor symptoms and non-motor symptoms, daily levodopa equivalent dose (LEDD) and safety. The specific research report is as follows:
[0110] 1. Information
[0111] 1.1 Research subjects
[0112] All 42 patients were from the outpatient clinic of the National Medical Master Studio of Hunan Hospital of Integrated Traditional Chinese and Western Medicine from January 1, 2020 to June 30, 2022. According to the time of the patient's visit, they were divided into two groups, namely, the 3-month treatment group (22 cases) and the 6-month treatment group (20 cases). Among the 22 cases in the 3-month treatment group, there were 12 males and 10 females; aged 56 to 87 years; the course of disease was 2 to 12 years; 12 cases of diabetes, 16 cases of hypertension, and 10 cases of coronary heart disease; 12 cases of family history, 5 cases of drinking, and 7 cases of smoking. Among the 20 cases in the 6-month treatment group, there were 12 males and 8 females; aged 64 to 87 years; the course of disease was 6 to 12 years; 4 cases of diabetes, 6 cases of hypertension, and 7 cases of coronary heart disease; 6 cases of family history, 2 cases of drinking, and 4 cases of smoking. This study has been reviewed by the Ethics Committee of Hunan Hospital of Integrated Traditional Chinese and Western Medicine (Lun Shen
[2022] No. 64).
[0113] 1.2 Diagnostic criteria
[0114] 1.2.1 Western medicine diagnostic criteria are consistent with the diagnostic criteria in the Diagnostic Criteria for Parkinson's Disease in China (2016 Edition). ① Parkinson's syndrome must be established before diagnosing PD. The core symptoms of Parkinson's syndrome are: bradykinesia, resting tremor and muscle rigidity, among which bradykinesia is a must and at least one of the other two symptoms is present. ② After confirming Parkinson's syndrome, diagnose PD according to the following criteria: (1) at least two supporting criteria exist; (2) there are no absolute exclusion criteria; (3) there are no warning signs.
[0115] 1.2.2 TCM Syndrome Differentiation Standards The syndrome differentiation standards for Yang deficiency-induced wind and dampness-stasis-blocking syndromes are formulated with reference to the "Expert Consensus on TCM Clinical Diagnosis and Treatment of Parkinson's Disease (Parkinson's Disease)" and the "National Standard TCM Clinical Diagnosis and Treatment Terminology Syndrome Treatment Summary". ① Main symptoms: bradykinesia, tremors of the head or limbs, stiff neck and back, stiff limbs, chills and cold limbs. ② Secondary symptoms: complexion Pale or dark tongue, unclear speech, dull expression or drooling at the corners of the mouth, dizziness, tinnitus, chest tightness, abdominal distension, soreness in the waist and knees, fixed pain that worsens at night, fatigue, sweating, edema of the limbs, insomnia, oliguria, constipation or diarrhea. ③ Tongue and pulse: pale and dark tongue, greasy or slippery tongue coating, petechiae or ecchymosis on the tongue, purple and thick sublingual collaterals, tortuous pulse, deep, thin, astringent and slippery pulse. Any two of the main symptoms plus any two or more of the secondary symptoms, combined with the patient's tongue and pulse, can clearly distinguish the syndrome.
[0116] 1.3 Inclusion criteria
[0117] ① Meet the above-mentioned Western medicine diagnosis and TCM syndrome differentiation standards; ② The age of onset is mostly over 50 years old, the onset is insidious, and the disease progressively worsens; ③ The patient gives informed consent and signs the informed consent form.
[0118] 1.4 Exclusion criteria
[0119] ① Patients with major diseases or severe liver and kidney dysfunction; ② Patients with poor compliance; ③ Pregnant or lactating women.
[0120] 2. Methods
[0121] 2.1 Treatment methods
[0122] The patients were treated with conventional western medicine combined with Panin I prescription. ① Conventional western medicine treatment. The treatment was carried out according to the standards in the "Guidelines for the Treatment of Parkinson's Disease in China". Drug treatment included compound levodopa preparations, dopamine receptor agonists, monoamine oxidase type B inhibitors, etc. Dopamine tablets (Shanghai Roche Pharmaceuticals Co., Ltd., approval number: National Medicine Standard H10930198, specification: 0.25g / tablet), 1 / 2 tablet each time, 3 times a day, orally; Carbidopa sustained-release tablets (Hangzhou Merck Pharmaceuticals Co., Ltd., approval number: National Medicine Standard HJ20160371, specification: 50mg carbidopa + 200mg levodopa / tablet), 1 tablet each time, 3 times a day, orally; Selegiline hydrochloride tablets (Anhui Baker Biopharmaceutical Co., Ltd., approval number: National Medicine Standard H20234721, specification: 5mg / tablet), 1 tablet each time, 2 times a day, orally; Pramipexole hydrochloride tablets (Zhejiang Jingxin Pharmaceutical Co., Ltd., approval number: National Medicine Standard H20183367, specification: 0.25mg / tablet), 1 / 2 tablet each time, 3 times a day, orally. The drug dosage is adjusted according to the patient's condition. Non-drug treatments include surgery, physical therapy, etc. ② Treatment with Chinese medicine. Panin No. 1 prescription: 9g of processed aconite, 9g of angelica, 15g of Morinda officinalis, 15g of Atractylodes macrocephala, 15g of Gastrodia elata, 5g of Scolopendra subspinipes, 9g of dried ginger, 15g of Acanthopanax senticosus, 15g of turtle shell, 15g of Pueraria root, 15g of cinnamon twig, 15g of white peony root, and 9g of licorice. Steam Gastrodia elata and take it, decocting the processed aconite for 30 minutes first, and then adding the remaining medicines to decoct together. Take 200mL warm in the morning and evening for 3 to 6 months.
[0123] 2.2 Observation of therapeutic efficacy
[0124] 2.2.1 Observation indicators ① The Unified Parkinson's Disease Rating Scale Part III (UPDRSⅢ) was used to evaluate the patient's motor function and flexibility, including tremor, rigidity, posture, gait, etc. The five-level scoring method was used, and normal, mild, mild, moderate, and severe were assigned 0, 1, 2, 3, and 4 points respectively. The higher the score, the more severe the condition. ② The Non-Motor Symptom Scale for Parkinson's Disease (NMSS) was used to evaluate the severity and frequency of the patient's non-motor symptoms, including memory, attention, sleep, fatigue, etc. The severity was assigned 1, 2, and 3 points according to mild, moderate, and severe, and the frequency was assigned 1, 2, 3, and 4 points according to very rarely, often, frequently, and very frequently. The higher the score, the more severe the condition. ③ Calculate LEDD. The oral PD drugs taken by the patient were converted into the dose of levodopa to measure the current total dose of oral Western medicine. ④ TCM syndrome score. Refer to the "Guidelines for Clinical Research of New Chinese Medicines" for evaluation. Main symptoms: bradykinesia, tremors of the head or limbs, stiff neck and back, stiff limbs, chills and cold limbs, scored as 0, 2, 4, and 6 according to the scale of none, mild, moderate, and severe. Secondary symptoms: complexion White or dark, unclear speech, dull expression or drooling at the corners of the mouth, dizziness and tinnitus, chest tightness and abdominal distension, soreness of waist and knees, fixed pain that worsens at night, fatigue, sweating, limb edema, insomnia and dreaminess, oliguria, constipation or diarrhea, assigned 0, 1, 2, 3 points according to none, mild, moderate, and severe. The higher the score, the more severe the condition. ⑤ Check blood routine, liver function, kidney function and other items, and observe adverse reactions such as nausea and vomiting.
[0125] 2.2.2 The efficacy standard is formulated in accordance with the "Traditional Chinese Medicine Industry Standard of the People's Republic of China·TCM Disease Diagnosis and Efficacy Standard". TCM syndrome score reduction rate = [(TCM syndrome score before treatment - TCM syndrome score after treatment) / TCM syndrome score before treatment] × 100%. Cured: symptoms and signs disappeared or basically disappeared, TCM syndrome score reduction rate ≥ 95%; markedly effective: symptoms significantly alleviated, 70% ≤ TCM syndrome score reduction rate < 95%; effective: symptoms improved, 30% ≤ TCM syndrome score reduction rate < 70%; ineffective: symptoms did not change significantly or worsened, TCM syndrome score reduction rate < 30%.
[0126] 2.3 Statistical methods
[0127] SPSS 27.0 software was used for analysis. The quantitative data that met the normal distribution were expressed as mean ± standard deviation. The t test was used to express the data, and the nonparametric test was used for the measurement data that did not conform to the normal distribution. The count data were expressed as rate (%) and the chi-square test was used. 2 P<0.05 indicated that the difference was statistically significant.
[0128] 3. Results
[0129] 3.1 Comparison of TCM syndrome efficacy between the two groups
[0130] The total effective rate was 72.73% in the 3-month treatment group and 100% in the 6-month treatment group. There was a significant difference between the two groups (P<0.05). The results are shown in Table 2. This suggests that Panin I prescription has a significant effect in treating PD of yang deficiency-induced wind and dampness-stasis type.
[0131] Table 2 Comparison of TCM syndrome efficacy between two groups [cases (%)]
[0132]
[0133] Note: Compared with the 3-month treatment group, * P<0.05
[0134] 3.2 Comparison of TCM syndrome scores between the two groups before and after treatment
[0135] After treatment, the TCM syndrome scores of both groups decreased compared with those before treatment, and the scores after 6 months of treatment were lower than those after 3 months of treatment, with a statistically significant difference (P<0.01). The results are shown in Table 3. This suggests that Panin I can significantly improve the TCM clinical symptoms of patients, which is time-dependent.
[0136] Table 3 Comparison of TCM syndrome scores between the two groups before and after treatment ( point)
[0137]
[0138] Note: Compared with the group before treatment, **P<0.01; compared with the group after 3 months of treatment, ## P﹤0.01
[0139] 3.3 Comparison of UPDRSⅢ and NMSS scores between the two groups before and after treatment
[0140] After treatment, the UPDRSⅢ and NMSS scores of both groups decreased compared with those before treatment, and the scores of the 6-month treatment group were lower than those of the 3-month treatment group. The intra-group and inter-group differences were statistically significant (P<0.01), as shown in Table 4. This suggests that Panin I prescription can significantly improve the patient's motor symptoms and non-motor symptoms compared with the previous time intervention.
[0141] Table 4 Comparison of UPDRSⅢ scores and NMSS scores between the two groups before and after treatment ( point)
[0142]
[0143] Note: Compared with the group before treatment, **P<0.01; compared with the group after 3 months of treatment, ## P﹤0.01
[0144] 3.4 Comparison of LEDD between the two groups before and after treatment
[0145] After treatment, LEDD in both groups decreased compared with that before treatment, and the LEDD in the 6-month treatment group was lower than that in the 3-month treatment group. The intra-group and inter-group differences were statistically significant (P<0.01). The results are shown in Table 5. It shows that with the increase of treatment time, the dosage of Western medicine gradually decreased, and the advantages of Chinese medicine gradually became prominent.
[0146] Table 5 Comparison of LEDD between the two groups before and after treatment ( mg)
[0147]
[0148] Note: Compared with the group before treatment, **P<0.01; compared with the group after 3 months of treatment, ## P﹤0.01
[0149] 3.5 Safety Assessment
[0150] During the treatment, no abnormal changes were observed in blood routine, liver function, kidney routine, etc. in the two groups of patients, and no adverse reactions occurred, indicating that the present invention has good safety and is convenient for patients to take for a long time.
[0151] 4. Conclusion
[0152] Panin I prescription has a good therapeutic effect on PD patients with yang deficiency-induced wind and dampness-stasis syndrome. It can improve patients' motor and non-motor symptoms, reduce the dosage of LEDD, alleviate the toxic and side effects of western medicine, reduce the degree of dependence on western medicine, delay the progression of the disease, and has the effect of increasing efficacy and reducing toxicity. It is worthy of clinical promotion and application.
Claims
1. A Chinese medicine composition for treating Parkinson's disease, characterized in that: The Chinese medicine composition comprises the following Chinese medicine ingredients in a weight distribution ratio: 6-15 parts of aconite root, 6-15 parts of angelica, 5-15 parts of Morinda officinalis, 6-30 parts of atractylodes macrocephala, 5-15 parts of gastrodia elata, 3-5 parts of scolopendra, 5-10 parts of dried ginger, 10-25 parts of acanthopanax senticosus, 15-24 parts of turtle shell, 10-15 parts of kudzu root, 5-15 parts of cassia twig, 10-30 parts of white peony root and 5-10 parts of liquorice.
2. A Chinese medicine composition for treating Parkinson's disease according to claim 1, characterized in that: The Chinese medicine composition comprises Chinese medicine ingredients in the following weight distribution ratio: 9 parts of aconite root, 9 parts of angelica, 15 parts of Morinda officinalis, 15 parts of Atractylodes macrocephala, 15 parts of Gastrodia elata, 5 parts of Scolopendra subspinipes, 9 parts of dried ginger, 15 parts of Acanthopanax senticosus, 15 parts of Carapace of Turtle, 15 parts of Pueraria root, 15 parts of cinnamon twig, 15 parts of white peony root, and 9 parts of liquorice.
3. A medicament for treating Parkinson's disease, characterized in that: The medicament comprises the Chinese medicine composition according to claim 1 or 2.
4. The medicament according to claim 3, characterized in that The medicament is suitable for treating Parkinson's disease of yang deficiency-induced wind, dampness-stasis and numbness-blocking type.
5. The medicament according to claim 3, characterized in that The drug achieves the treatment of Parkinson's disease by changing the morphological structure of mitochondria, and / or activating the activity of respiratory chain complexes I to IV of substantia nigra mitochondria, and / or improving mitochondrial energy metabolism.
6. The medicament according to claim 3, characterized in that The agent inhibits the abnormal upregulation of mitochondrial biogenesis and promotes ATP production by regulating the AMPK / SIRT1 / PGC / 1α pathway.
7. The medicament according to claim 3, characterized in that The agent improves mitochondrial energy metabolism by regulating metabolic disorders of serum phenylalanine, tyrosine and tryptophan biosynthesis pathways.
8. The medicament according to claim 3, characterized in that The concentration of the agent is 1.2 to 4.8 g.mL -1 .
9. The medicament according to claim 8, characterized in that The concentration of the agent is 4.8 g.mL -1 .
